ThinkSabio

$AGMB

$8.81▲ -2.8% YTD

6 SEC 13D/G filings tracked · Last updated Oct 13, 2026

Filing History
News
AGMB ▼ -2.8% - AgomAb Therapeutics NV
CP $8.81▲ -2.8%Oct 13, 2026 · ThinkSabio Blog

$AGMB - Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease…

News
AGMB ▲ +4.3% - AgomAb Therapeutics NV
CP $9.22▲ +4.3%Oct 8, 2026 · ThinkSabio Blog

$AGMB - Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation…

News
AGMB ▲ +0.8% - AgomAb Therapeutics NV
CP $11.10▲ +0.8%Oct 1, 2026 · ThinkSabio Blog

$AGMB - Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease…

News
AGMB ▼ -6.0% - AgomAb Therapeutics NV
CP $12.28▲ -6.0%Sep 14, 2026 · ThinkSabio Blog

$AGMB - Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study…

News
AGMB ▼ -8.1% - AgomAb Therapeutics NV
CP $12.81▲ -8.1%Sep 11, 2026 · ThinkSabio Blog

$AGMB - Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors…

News
AGMB ▲ +8.6% - AgomAb Therapeutics NV
CP $14.83▲ +8.6%Sep 3, 2026 · ThinkSabio Blog

$AGMB - Agomab to Participate in Upcoming Investor Conferences…